The Ensign Group, Inc. (ENSG)
NASDAQ: ENSG · Real-Time Price · USD
151.75
+1.75 (1.17%)
Aug 1, 2025, 4:00 PM - Market closed
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $167.57, which forecasts a 10.43% increase in the stock price over the next year. The lowest target is $156 and the highest is $175.
Price Target: $167.57 (+10.43%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $155 → $165 | Hold | Maintains | $155 → $165 | +8.73% | Jul 28, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $165 → $170 | Buy | Maintains | $165 → $170 | +12.03% | Jul 28, 2025 |
| Macquarie | Macquarie | Buy Maintains $159 → $156 | Buy | Maintains | $159 → $156 | +2.80% | May 2, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $155 → $160 | Buy | Maintains | $155 → $160 | +5.44% | Feb 7, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $155 | Buy | Reiterates | $155 | +2.14% | Feb 6, 2025 |
Financial Forecast
Revenue This Year
5.02B
from 4.26B
Increased by 17.71%
Revenue Next Year
5.51B
from 5.02B
Increased by 9.87%
EPS This Year
6.43
from 5.12
Increased by 25.62%
EPS Next Year
7.09
from 6.43
Increased by 10.29%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 5.2B | 5.7B | 6.3B |
| Avg | 5.0B | 5.5B | 6.0B |
| Low | 4.8B | 5.2B | 5.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 21.7% | 14.0% | 14.6% |
| Avg | 17.7% | 9.9% | 9.8% |
| Low | 12.6% | 3.5% | 4.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 6.65 | 7.36 | 8.16 |
| Avg | 6.43 | 7.09 | 7.82 |
| Low | 6.14 | 6.71 | 7.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 29.8% | 14.4% | 15.0% |
| Avg | 25.6% | 10.3% | 10.2% |
| Low | 20.0% | 4.4% | 2.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.